Brief: Alterity Therapeutics Completes Last Patient Visit In ATH434-202 Open-Label Phase 2 Trial In Multiple System Atrophy
27/03/2025 11:34
March 27 (Reuters) - Alterity Therapeutics Ltd ATH.AX: ALTERITY THERAPEUTICS COMPLETES LAST PATIENT VISIT IN ATH434-202 OPEN-LABEL PHASE 2 TRIAL IN MULTIPLE SYSTEM ATROPHY ALTERITY THERAPEUTICS LTD: TOPLINE DATA EXPECTED MID-YEAR 2025 Source text: ID:nGNX94c24g Further company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital